23 results about "Antibody receptor" patented technology

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The invention belongs to the technical field of biology, and particularly relates to a fusion protein and application thereof in competitive inhibition of MDM2 and further recovery of TP53 activity. The fusion protein provided by the invention comprises an antibody fragment, a modified progesterone receptor and an RING subunit of an antibody receptor Trim21 which are connected in sequence, has a composite structure of an antibody and a part of subunits of the Trim21, can specifically degrade a target protein, competitively inhibits MDM2 while degrading the target protein, further recovers the activity of a P53 gene, and has a good application prospect. The anti-tumor effect is also realized.

The invention relates to a chimeric autoantibody receptor (CAAR) comprising an autoantigen of a Contactin-associated protein-like 2 (CASPR2) protein or one or more autoantigenic fragments thereof. The invention relates further to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid comprising a sequence encoding an autoantigen, wherein said autoantigen comprises or consists of Contactin-associated protein-like 2 (CASPR2) or one or more fragments thereof, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. The invention further relates to a nucleic acid vector comprising a nucleic acid molecule encoding the chimeric autoantibody receptor (CAAR) of the invention. The invention relates further to a genetically modified cell comprising a nucleic acid molecule or a vector of the invention and / or expressing a CAAR according to the invention.

The invention relates to the technical field of detection methods, in particular to a method for detecting serum amyloid protein A. The specific technical scheme is as follows: after a serum amyloid protein A secondary antibody donor bead complex and a serum amyloid protein A primary antibody receptor bead complex are mixed with an antigen to be detected, a light-emitting signal value is detected. The method for detecting the serum amyloid protein A disclosed by the invention has the advantages of wide detection limit, homogeneous phase, no washing, simplicity and convenience in operation, good specificity, good repeatability and good anti-interference performance, can be used for rapidly detecting infection markers, and has clinical application potential.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

The present invention relates to a chimeric autoantibody receptor (CAAR) capable of targeting immune cells to B cells that produce autoantibodies. The CAAR comprises an autoantigen or a fragment thereof that binds to autoantibodies associated with a neuroautoimmune disease predominantly targeting the central nervous system. The present invention relates to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid molecule comprising: a sequence encoding an autoantigen or a fragment thereof that binds to autoantibodies associated with a neuroautoimmune disease predominantly targeting the central nervous system; a sequence encoding a transmembrane domain; and a sequence encoding an intracellular signaling domain. In one embodiment, the autoantigen encoded by the nucleic acid sequence comprises or consists of the following: N-methyl-D-aspartic acid receptor (NMDAR) or one or more NMDAR fragments. The present invention further relates to the chimeric autoantibody receptor (CAAR) protein of the present invention, a vector comprising a nucleic acid molecule encoding the chimeric autoantibody receptor (CAAR) of the present invention, a genetically modified immune cell comprising a nucleic acid molecule encoding CAAR, and the use of the immune cell in the treatment or prevention of a neuroautoimmune disease predominantly targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

Chimeric autoantibody receptors (CAARs) can include separate signaling and recognition constructs that are able to bind ligands that target autoantigens made of conventional amino acids, non-conventional amino acids, carbohydrates, or nucleic acids. Additionally, the present disclosure describes cells modified to express such constructs and the use of such constructs and / or cells in the treatment of autoimmune disease.

A modified immune cell that does not express a T-cell receptor (TCR) and comprises a CD3 antibody receptor complex. Also relates to a pharmaceutical composition comprising said modified immune cell and a bispecific antibody, and the use of said pharmaceutical composition in the preparation of a medicament.

The invention provides a chimeric autoantibody receptor of a targeted acetylcholine receptor antibody, a CAAR-T cell and application of the chimeric autoantibody receptor in a medicine for preventing and treating myasthenia gravis, and belongs to the technical field of biological medicines. The invention provides a chimeric autoantibody receptor (CAAR) targeting an acetylcholine receptor antibody, which is characterized in that three extracellular domains of an AChR alpha subunit are connected in series through L1 and L2 connecting peptides or G4S connecting peptides to form an extracellular domain, and meanwhile, CD3 gamma only containing an ITAM motif is used as a signal transduction domain. The CAAR is expressed on the surface of a T cell, and the obtained CAAR-T not only has relatively strong binding capacity with an anti-AChR antibody, shows a relatively strong killing effect on pathogenic B cells expressing the anti-AChR antibody, can effectively relieve the symptom of myasthenia gravis, but also has relatively low risk of inducing cytokine storm, and has good drug safety.

The invention discloses a chimeric AQP4 antibody receptor, a CAAR-T cell and application. The chimeric AQP4 antibody receptor comprises an AQP4 antibody binding domain, a costimulatory domain and an activation domain which are sequentially connected from an amino terminal to a carboxyl terminal, wherein the AQP4 antibody binding domain is the full length of AQP4 M1 or the full length of AQP4 M23, the nucleotide sequence of the full length of AQP4 M1 is as shown in SEQ ID NO: 4, and the nucleotide sequence of the full length of AQP4 M23 is as shown in SEQ ID NO: 5. The full-length AQP4 M1 and M23 subtype proteins are expressed on the surface of the T cell through a gene editing technology, the constructed CAAR-T cell can specifically recognize and attack B cells secreting pathogenic antibodies and retain other normal B cell subsets, the effect is remarkable, and the risk caused by long-term use of biological agents is reduced.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

The invention provides application of chimeric autoantibody receptor T cells of an anti-AChR antibody in preparation of drugs for preventing and / or treating myasthenia gravis, and belongs to the technical field of biological drugs. The invention relates to a chimeric autoantibody receptor of a targeted acetylcholine receptor antibody. The chimeric autoantibody receptor comprises an AChR alpha subunit extracellular structural domain and a signal transduction structural domain CD3 epsilon, the CD3 epsilon only containing one ITAM motif is used as a signal transduction structural domain, and the safety level of cell factors can be effectively maintained. The CAAR-T cell prepared by the invention can accurately recognize and kill pathogenic cells with specific BCR, and can effectively relieve the symptom of mouse myasthenia. Therefore, the invention provides a more accurate and effective strategy for MG immune targeted therapy.

This invention relates to the technology of antibodies, and more specifically, to antibodies that bind to the IL-18 receptor, IL-18 receptor activators, and their use. The invention provides antibodies that specifically bind to IL-18R1 and IL-18RAP with high affinity, and further provides bispecific antibodies that can efficiently bind both IL-18R1 and IL-18RAP simultaneously. These bispecific antibodies are novel IL-18 receptor activators that can activate the intracellular signaling pathway mediated by IL-18R1 / IL-18RAP, exert biological functions similar to IL-18 both in vitro and in vivo, and possess broad immunostimulatory effects and remarkable antitumor activity. Furthermore, they possess controllable activating activity, excellent molecular stability, and in vivo pharmacokinetic characteristics, which are advantageous for fully exhibiting antitumor efficacy in vivo, and offer prospects for a wide range of antitumor clinical applications.

Methods and systems for improving or enabling delivery of antibodies, immunoglobulin receptors, or immunotherapy agents across the Blood-Brain Barrier (BBB) are disclosed. Exosomes are derived from stem cells, immune cell progenitors, or immune cells, and are loaded with an antibody, immunoglobulin receptor, or antibody fragment. Focused energy, preferably low-intensity focused ultrasound, is applied to a region of the BBB of a patient, and loaded exosomes are administered to the patient. Exosomes target the region for delivery of the loaded antibody, receptor, or fragment, either by traversing the BBB at the region or releasing the loaded antibody to neural tissue at the region.

The invention discloses a plasmid vector, a chimeric MOG antibody receptor T cell and application of the chimeric MOG antibody receptor T cell. The plasmid vector comprises a chimeric autoantibody receptor, and the chimeric autoantibody receptor is sequentially composed of a signal peptide, an extracellular fragment of an MOG antigen, a transmembrane region CD8alpha, a costimulatory domain 4-1BB and an activation domain CD3xi from an amino terminal to a carboxyl terminal; the base sequence of the signal peptide is as shown in SEQ ID NO: 1; the base sequence of the extracellular fragment of the MOG antigen is as shown in SEQ ID NO: 2; the base sequence of the transmembrane region CD8 alpha is as shown in SEQ ID NO: 3; the base sequence of the costimulatory domain 4-1BB is as shown in SEQ ID NO: 4; the base sequence of the activation domain CD3xi is as shown in SEQ ID NO: 5; the chimeric MOG antibody receptor T cell provided by the invention can specifically kill pathogenic B cells which generate the MOG antibody with high selectivity, so that precise treatment on MOGAD is realized.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.

Methods of making a chimeric antigen receptor (CAR)-immune cell or chimeric autoantibody receptor (CAAR)-immune cell, e.g., with an enzyme capable of performing targeted genomic integration, are provided.

This application discloses a chimeric AQP4 antibody receptor, CAAR-T cells, and their applications, comprising an AQP4 antibody-binding domain, a co-stimulatory domain, and an activation domain sequentially linked from the amino terminus to the carboxyl terminus; wherein the AQP4 antibody-binding domain is either the full-length AQP4 M1 or the full-length AQP4 M23, the nucleotide sequence of the full-length AQP4 M1 is shown in SEQ ID NO:4, and the nucleotide sequence of the full-length AQP4 M23 is shown in SEQ ID NO:5. This application utilizes gene editing technology to express the full-length AQP4 M1 and M23 isotype proteins on the surface of T cells. The constructed CAAR-T cells can specifically recognize and attack B cells secreting pathogenic antibodies while preserving other normal B cell subsets, demonstrating significant efficacy and reducing the risks associated with long-term use of biological agents.

The invention provides a CAAR-T cell for treating myasthenia gravis and a medicine thereof, and belongs to the technical field of biological medicines. The chimeric autoantibody receptor of the targeted acetylcholine receptor antibody comprises the following structural domains which are connected in series: an AChR alpha subunit extracellular structural domain, a transmembrane region structural domain, a co-stimulatory molecule intracellular structural domain and a signal transduction structural domain. ECD1, ECD2 and ECD3 in the extracellular structural domain of the AChR alpha subunit are connected in series through an L1 connecting peptide and an L2 connecting peptide or two G4S connecting peptides, and the combining capacity with an anti-AChR antibody can be improved, so that a relatively strong killing effect on pathogenic B cells expressing the anti-AChR antibody is shown, the symptom of myasthenia gravis is effectively relieved, and good drug safety is achieved.

The invention relates to compositions and methods for chimeric autoantibody recipient cells of acetylcholine receptors. The present invention includes chimeric autoantibody receptors (CAARs) having specificity against acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAARs, polynucleotides encoding the CAARs, vectors and recombinant cells comprising the polynucleotides encoding the CAARs, e.g., T cells comprising the CAARs.

The invention discloses a target receptor ubiquitination induced antibody fusion protein and application thereof. The antibody fusion protein comprises (a) an antibody structural domain capable of being combined with a tumor-associated antigen receptor; (b) a membrane binding type E3 ubiquitin ligase binding module fused with the antibody structural domain, the binding module is an RSPO2 FU (F109A) structural domain, and the amino acid sequence of the binding module is shown as SEQ ID No.3; the antibody fusion protein can be combined with a tumor-associated antigen receptor and a membrane binding type E3 ubiquitin ligase RNF43 and / or ZNRF3 at the same time. The antibody fusion protein can significantly enhance the tumor-associated antigen receptor intermediation and lysosome delivery efficiency, and overcomes the problem of insufficient reduction of the level of the existing antibody receptor; the compound can be applied to treatment of solid tumors related to tumor-related antigen receptors and possibly extends to other diseases related to receptor degradation.

The present disclosure relates to chimeric autoantibody receptors (CAARs) specific for an autoantibody that targets Epstein-Barr Virus nuclear antigen 1 (EBNA1) molecular mimics - GlialCAM, aB Crystallin (CRYAB), and Anoctamin-2 (ANO-2), vectors comprising the CAARs, and genetically modified cells comprising the CAARs. Pharmaceutical compositions and kits comprising the same are provided, as well as methods of diagnosing and methods of treating, preventing, and / or managing multiple sclerosis are provided.